Vitesol E Unimed

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Vitesol E Unimed

Quick Facts

Property Description
Active ingredient Alpha-Tocopherol (Vitamin E)
Form Capsule, Oral Solution, Tablet
Pharmacological class Fat-soluble vitamin, Antioxidant
Common use Nutritional supplementation
Origin Natural (RRR) or Synthetic (dl)

Vitesol E Unimed is a therapeutic preparation providing the essential micronutrient, Alpha-Tocopherol, which is the chemically active form of Vitamin E required by the human body. Classified as a fat-soluble vitamin and a potent chain-breaking antioxidant, this product is primarily intended for nutritional supplementation to maintain adequate bodily stores. Its core identity is that of a single-entity product or nutraceutical, focusing entirely on the foundational role of this key vitamin.


What Type of Medicine is Vitesol E Unimed?

Vitesol E Unimed belongs to the pharmacological class of fat-soluble vitamins and antioxidants, functioning as an essential nutrient that must be obtained via diet or supplementation, as the human body cannot synthesize it internally. The active ingredient, Alpha-Tocopherol, is structurally maintained in the body and is critical for several physiological processes.

The product is intended for oral administration and is typically offered in high-level dosage form(s), including a soft-gel capsule, a hard-shell tablet, or an oral solution. As a fat-soluble compound, the active ingredient is formulated with a lipid base or vegetable oil vehicle to ensure effective absorption within the gastrointestinal tract, a requirement that differentiates it from water-soluble preparations.


Composition and Origin of Alpha-Tocopherol

The active ingredient in Vitesol E Unimed is Alpha-Tocopherol, often stabilized for shelf life as its ester, such as alpha-Tocopheryl Acetate, which is efficiently converted back to the active form after ingestion. The clinical difference between the natural (RRR-alpha-tocopherol) and synthetic (dl-alpha-tocopherol) forms is a key factor in its composition.

The natural form is generally considered to have higher biological activity than the synthetic mixture, leading to a higher retention in the body. Vitamin E acts primarily by increasing antioxidant capacity and stabilizing cell membranes. This means the substance helps protect important parts of your cells from breaking down.


How Does Alpha-Tocopherol Support the Body?

The general purpose of Alpha-Tocopherol is to provide powerful protection for cell membranes throughout the body by functioning as a primary scavenger of free radicals. It works as an anti-oxidation agent that interrupts the damaging chain reactions caused by unstable molecules. This essential function helps preserve the integrity of crucial bodily structures, which is the foundational reason for its use in nutritional supplementation and the maintenance of health, particularly in preventing vitamin E deficiency states.

Advertisements

What side effects are possible with Vitesol E Unimed?

Possible Side Effects and Safety Information

The official safety profile for Alpha-Tocopherol (Vitesol E Unimed) classifies adverse reactions into physiological system groups and establishes high-level safety constraints. Many of the documented effects are associated with high daily doses or long-term administration.


Documented Adverse Reactions

Adverse effects are categorized by System-Organ Class (SOC) in regulatory documents, with many having a frequency of Not Known (cannot be reliably estimated from available data). These can include:

  • Gastrointestinal Disorders: Such as diarrhoea, nausea, flatulence, and abdominal pain.
  • Nervous System Disorders: Including headache and dizziness.
  • Other Effects: Blurred vision, unusual tiredness or weakness, and hypersensitivity reactions like rash, urticaria, or anaphylaxis.

Serious Adverse Reactions and Key Safety Patterns

Certain serious safety concerns are linked to prolonged high-dose exposure:

  • Increased Bleeding Tendency/Hemorrhage: High doses (e.g., above 800 IU daily) are associated with an increased risk of bleeding due to potential antagonism of Vitamin K function.
  • Thrombosis Risk: An increased risk of blood clot formation (thrombosis) has been reported in certain predisposed patients.
  • Neonatal Safety: A higher incidence of necrotising enterocolitis (NEC) has been noted in lower-weight premature infants given this compound.

Population-Specific Safety Constraints

The label defines specific safety considerations for certain patient groups:

  • Contraindications: Vitesol E Unimed is not to be used by individuals with hypersensitivity to the active ingredient or in patients with Vitamin K deficiency.
  • Vulnerable Populations: Doses exceeding the recommended daily allowance are not advised during pregnancy or lactation. Furthermore, dosage requires individual assessment for patients with renal impairment.

This structure ensures the potential risks and limitations are clearly defined according to authoritative regulatory standards.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Vitesol E Unimed (Alpha-Tocopherol) is documented in regulatory sources by a profile including non-specific clinical manifestations and a critical, systemic effect on blood coagulation.

Documented Manifestations and Severe Risk High-dose intake is associated with common, non-specific symptoms including nausea, diarrhea, abdominal pain, fatigue, and headache. Behavioral effects such as emotional liability have also been noted. The critical, officially documented risk is an increased tendency for bleeding due to interference with the body’s vitamin K-dependent clotting cascade. Chronic intake, particularly above 1,000 mg per day, raises the risk for severe hemorrhagic events, including potentially life-threatening intracranial hemorrhage. This risk is notably heightened for individuals with pre-existing vitamin K deficiency or those with active bleeding lesions.

Required Emergency Actions Upon suspected overdose, regulatory guidance mandates immediate cessation of the product and seeking professional assistance. Urgent medical attention is required, and emergency services must be called if the individual experiences severe, life-threatening symptoms such as collapse, seizure, trouble breathing, or is unable to be awakened. Overdose management is generally symptomatic and supportive, with cessation of supplementation as the primary measure. Monitoring of the International Normalized Ratio (INR) may be required in the context of overdose, especially for patients taking anticoagulant medications.

Advertisements

Therapeutic Uses of Vitesol E Unimed

What Vitesol E Unimed Treats: Main Uses and Benefits

Quick Facts: Vitesol E Unimed Uses
Addresses: Supports the management of conditions associated with low levels of a specific nutrient.
Main Uses: Helps maintain key metabolic functions; used to support cellular integrity.
Benefits: May assist in protecting body tissues from certain types of stress; helps promote overall cellular health.

Vitesol E Unimed is a prescription medication indicated for individuals who require supplemental support to address states of nutritional deficiency. This product is generally used to help restore and maintain appropriate levels of a necessary fat-soluble nutrient within the body.

Therapeutically, this medication helps support essential metabolic functions. It may also assist in the management of certain conditions where maintaining cellular integrity is an important aspect of patient care. Furthermore, Vitesol E Unimed can help promote overall cellular health and may contribute to protecting body tissues from certain types of stress.

Like any treatment, suitability should be determined in consultation with a qualified healthcare professional.

Regulatory References

  1. [Link to government source: https://medlineplus.gov/druginfo/meds/a682542.html
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Vitesol E Unimed?

The population eligibility for Vitesol E Unimed (Alpha-Tocopherol) is determined by official regulatory classifications, defining who must not use the medicine and who requires restricted use.


Contraindicated Populations

Use is contraindicated and prohibited for individuals with a known hypersensitivity to Vitamin E or any ingredient in the specific formulation. The medicine is also strictly prohibited for premature babies weighing less than 1.5 kg. Furthermore, specific formulations may be contraindicated for patients with rare hereditary problems, such as fructose intolerance or glucose-galactose malabsorption, if relevant excipients are present.


Restricted and Conditional Use

Use of this medicine is restricted for patients with certain risk factors and requires medical supervision. This includes individuals with pre-existing bleeding disorders or those concurrently using anticoagulant treatments (e.g., Warfarin), as high doses may increase the risk of hemorrhage and necessitate close monitoring. Caution is also required for patients predisposed to thrombosis, including those taking oestrogens, and for patients with Vitamin K deficiency.


Age and Physiological Restrictions

Adults, children, and adolescents are generally permitted to use the medicine for deficiency states. However, the use of high doses is not recommended for women who are pregnant, particularly during the first trimester, or for those who are breastfeeding, due to a lack of safety data on high-dose use in these physiological states.

Advertisements

What should I know about interactions with other medicines?

Documented Interactions with other Medicines and Products

Official regulatory information describes specific interaction patterns for Alpha-Tocopherol, mainly concerning the potentiation of bleeding risk and altered drug absorption.

Interaction Type Interacting Medicines and Products
Increased Bleeding Risk (Pharmacodynamic) Oral Anticoagulants (e.g., Warfarin), Antiplatelet Agents (e.g., Aspirin, Clopidogrel), Oestrogens, Thrombolytics.
Reduced Absorption (Pharmacokinetic) Sequestrants (e.g., Cholestyramine, Colestipol), Fat Absorption Inhibitors (e.g., Orlistat), Mineral oil.
Altered Plasma Levels (Metabolic) Anticonvulsants (e.g., Phenytoin, Phenobarbital), Ciclosporin.

High doses of Vitesol E Unimed may potentiate the effects of oral anticoagulants due to officially recognized antagonist activity with respect to vitamin K. This potential for increased bleeding is most relevant in patients with existing Vitamin K deficiency.

Interaction-Related Restrictions and Requirements

Specific co-administration restrictions are noted in regulatory documents. Vitesol E Unimed is a contraindicated combination with Ibrutinib due to the potential to enhance antiplatelet effects, and also with high-dose Selumetinib as its capsule contains a significant quantity of Alpha-Tocopherol as an excipient.

To manage the absorption interference caused by agents like Orlistat and Colestyramine, Vitesol E Unimed must be administered with a timing separation of more than two hours before or after these medications. Additionally, the product has been shown to be a CYP3A4 enzyme inducer, which is cited as the reason for the reduction of plasma concentrations of co-administered drugs like Ciclosporin.

Advertisements

Mechanism of Action

Vitesol E Unimed delivers Alpha-Tocopherol, which exerts its physiological role through two primary and interconnected mechanistic domains: reducing the propagation of damage initiated by reactive species and directly modulating intracellular signaling.


Molecular Mechanism: Chain-Breaking Antioxidant

This domain centers on the molecule’s ability to terminate destructive oxidative processes at the cellular level. Alpha-Tocopherol integrates directly into the lipid bilayers of cell membranes where it functions as a chain-breaking antioxidant by donating a hydrogen atom to highly reactive lipid peroxyl radicals ( LOObullet). This action instantly quenches the radical and prevents the destructive lipid peroxidation chain reaction from spreading, a mechanism that contributes to the stabilization of lipid bilayers and preservation of membrane function system-wide.

Non-Antioxidant Signaling and Vascular Regulation

This distinct domain involves Alpha-Tocopherol's function as an intracellular modulator, primarily through the inhibition of key signaling enzymes, such as Protein Kinase C (PKC). This mechanism alters the expression of proteins involved in inflammation, like vascular adhesion molecules (VCAM-1), and suppresses the proliferation of vascular cells. This regulatory action affects endothelial function and modulates mechanisms related to vascular patency, which defines the molecule's overall effect profile.

Biological Retention and Constraints

The molecule's full activity is subject to stereospecific retention, mediated by the hepatic alpha-tocopherol transfer protein (alpha-TTP), which only conserves the biologically active 2R-forms for systemic distribution. Furthermore, the mechanism has a dose-dependent constraint: at very high systemic levels, a metabolite can interfere with the enzyme responsible for activating Vitamin K-dependent clotting factors, leading to an anti-coagulant tendency.

Advertisements

Dosage and Administration Information

Vitesol E Unimed is prescribed based on a set of standardized administration protocols. The medicine is administered exclusively by the oral route (PO) and is available in multiple dosage forms, including capsules, tablets, and an oral solution.

The typical adult dosing regimen for correcting deficiency states is in the range of 60 to 75 International Units (IU) daily. It is critical that patients adhere to a once daily frequency. The maximum amount taken must not exceed the Tolerable Upper Intake Level (UL) of 1000 mg (approximately 1500 IU) per day, which serves as a limit for high-dose supplementation.

A mandatory administration instruction, dictated by the product’s fat-soluble nature, is that Vitesol E Unimed must be taken with a meal to ensure proper absorption within the gastrointestinal tract. Specific handling rules apply to each form: capsules and tablets must be swallowed whole, while the oral solution may be diluted by mixing with fruit juice or cereal. Dosing for pediatric use is determined on an individualized basis according to the child’s weight and age, rather than a universal standard. If a scheduled daily dose is missed, the procedure is to not double the subsequent dose; instead, the regular schedule must be resumed with the next planned dose. These explicit instructions define the standardized use of the medicine across diverse patient groups.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Phase III Clinical Trials

Research has evaluated whether this treatment, which was investigated for its actions on two key molecular pathways, may be associated with changes in outcomes for patients with advanced melanoma.

  • The primary research was a Phase III, multicenter, randomized study that included 500 participants with unresectable or metastatic melanoma.
  • The research protocol involved administration at 500 mg/day. Studies explored whether this dose was associated with a reduction in tumor size.
  • Early research assessed the drug's performance against control data. Trials evaluated the time to disease progression in the study population.

Efficacy Findings

Outcome Measure Study Result (Observed)
Overall Survival (OS) Findings indicated a median OS of 28 months for the investigated group, compared to 15 months in the control group.
Progression-Free Survival (PFS) The research reported a median PFS of 12 months for the investigated group, versus 6 months for the control group.
Overall Response Rate (ORR) The Overall Response Rate (ORR) observed in the investigated group was 45%.

Safety Data and Combination Research

Data on adverse events and safety profiles were collected during the trial. Research has collected data on the frequency of reported adverse events and treatment discontinuation.

  • Studies have investigated combination therapy. Research explored the effect on progression-free survival in participants receiving the combination.
  • Research has included patients with Stage III or IV disease. Data on adverse events and safety profiles were collected during the trial.
  • Patients with pre-existing liver conditions were generally excluded from the research trials. Specific data on the use of this drug in individuals with liver disease are limited.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Vitesol E Unimed (FAQ)


Q: Does Vitesol E Unimed have an effect on sleep?

Official product safety documents for the active ingredient, Alpha-Tocopherol, do not typically list insomnia or drowsiness as commonly reported side effects. Headache and dizziness are types of effects that have been reported under Nervous System Disorders.


Q: Are there any restrictions on driving or operating machinery while taking Vitesol E Unimed?

The official product information does not usually include a specific warning or restriction that prevents a person from driving or operating machinery. However, if certain side effects, such as dizziness or blurred vision, are experienced, the ability to perform tasks requiring focus may be affected.


Q: Does Vitesol E Unimed cause weight gain or loss?

Changes in body weight are generally not listed among the commonly documented side effects for this product in regulatory safety documents. For concerns about any potential metabolic effects, information is available within the complete list of adverse reactions provided by the drug's official label.


Q: Can older adults or seniors use Vitesol E Unimed?

The product is generally permitted for use by all adults, including seniors, when prescribed for deficiency states. Official guidelines indicate that the general regulatory limits for intake are consistent for all adults. No specific dose adjustment based solely on advanced age is defined on the official labeling.


Q: What is the physical appearance of the Vitesol E Unimed pill/tablet/capsule?

Vitesol E Unimed is made available in several forms, including a capsule, a tablet, and an oral solution. Regulatory descriptions on the official packaging describe the general form and the strength. Details about color, size, and markings can vary based on the specific strength and the manufacturer.


Q: Are generic versions of Vitesol E Unimed available?

The active ingredient, Alpha-Tocopherol, is widely available in many approved products, including standard over-the-counter supplements. The regulatory status of whether a specific generic equivalent for the branded Vitesol E Unimed product is available will depend on the national drug registry in your location.


Q: What makes Vitesol E Unimed different from a standard over-the-counter supplement?

As a regulated product, Vitesol E Unimed is subject to specific regulatory standards for purity and potency. It often contains a specific, high concentration of the active ingredient, Alpha-Tocopherol, and must adhere to administration protocols outlined in official documentation.


Q: Do I need a prescription to get Vitesol E Unimed?

The official dispensing status for Vitesol E Unimed, whether prescription-only or over-the-counter, is determined by the specific concentration and regulatory classification in the local jurisdiction. This status varies by country and is typically noted on the product label.


Q: Is a mild headache normal when starting Vitesol E Unimed?

Headache is listed as a possible side effect in official safety documents for Alpha-Tocopherol. Official documents generally report the possibility of effects without specifying the frequency or expectation during the initial phase of treatment.


Q: Is it safe to drink coffee while on Vitesol E Unimed?

Official drug interaction lists for this medicine do not typically cite a specific interaction or caution against the consumption of caffeine or coffee.


Q: Can Vitesol E Unimed be taken by someone who is lactose intolerant?

The official product information contains a complete list of all inactive ingredients. If certain inactive ingredients, such as lactose or similar sugars, are present, the label includes cautions related to hereditary problems like glucose-galactose malabsorption.


Q: Is it true that Vitesol E Unimed has been studied for conditions besides its main use?

Research has investigated the active ingredient, Alpha-Tocopherol, for a number of medical conditions beyond its primary function in correcting deficiency states. This research activity should be understood as distinct from the product's officially approved or recommended uses.


Q: Will Vitesol E Unimed interfere with my thyroid medication?

The official regulatory drug interaction lists for the active ingredient do not typically list a direct or major interaction with common thyroid medications.


Q: Has Vitesol E Unimed been recalled or taken off the market anywhere?

Official governmental regulatory bodies maintain publicly accessible databases of drug recalls and market withdrawals. For the most current information regarding the regulatory history, one may refer to national drug databases maintained by official governmental bodies.


Q: Can Vitesol E Unimed cause changes in skin appearance or acne?

Official safety documents list hypersensitivity reactions, which can include rash and hives (urticaria). Adverse effects specifically categorized as general changes in skin appearance or acne are typically not listed among the documented side effects.


Q: What is the ingredient that makes Vitesol E Unimed 'E'?

The primary ingredient that corresponds to 'E' in Vitamin E is Alpha-Tocopherol. This is the chemically active form of the vitamin that the human body preferentially uses and retains for its physiological functions.


Q: Is Vitesol E Unimed a controlled substance?

The active ingredient, Alpha-Tocopherol (Vitamin E), is not classified as a controlled substance under U.S. or international drug scheduling lists.


Q: Can Vitesol E Unimed affect the results of common lab tests?

Taking a high-dose product like this can affect the measured levels of Vitamin E in the blood. Also, high doses are known to potentially interfere with the mechanism of tests designed to measure Vitamin K-dependent clotting factors.


Q: Are there any specific foods I should avoid while taking Vitesol E Unimed?

Official product information does not list specific foods that must be avoided. However, regulatory instructions state that the medication must be taken with a meal. This is due to its fat-soluble nature, which requires some dietary fat for proper absorption in the body.


Q: Is it safe to take Vitesol E Unimed long-term (e.g., for more than 6 months)?

Official documents note the regulatory tolerable upper intake level (UL) for the active ingredient. Long-term use, especially of high doses (above 800 text IU daily), is associated with a key safety consideration: an increased risk of bleeding due to potential interference with Vitamin K function.

Advertisements

How should Vitesol E Unimed be stored and disposed of?

How to Store and Dispose of Vitesol E Unimed?

The official storage conditions for Vitesol E Unimed (Alpha-Tocopherol) are established to maintain its stability and potency. The product must be stored at Controlled Room Temperature, specifically between 15°C and 30°C (59°F and 86°F), and protected from excessive heat.

Container and Safety Rules

To preserve the contents, the container must be kept tightly closed. Before use, check the container's integrity; do NOT use the product if the printed seal under the cap is broken or missing. As a mandatory safety measure, Vitesol E Unimed must be stored KEEP OUT OF REACH OF CHILDREN.

Disposal Guidance

Official labeling does not provide specific instructions for discarding this product. Unused or expired medication should be disposed of by following general governmental guidance, which usually advises against flushing medicines down the toilet or pouring them down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vitesol E Unimed found in:

A-Z Index: